Latest News Archive

Please select Category, Year, and then Month to display items

Fighting COVID-19: Here is how we are helping

16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish

Farmovs — In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19.

The trial is expected to include more than 45 countries worldwide, including a number of South African sites.

Farmovs
FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients.

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe. FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.

News Archive

National accolade for Dr Philemon Akach

2013-10-21

Dr Philemon Akach
Photo: Sonia Small
21 October 2013

Excellence in Teaching and Learning is highly regarded at the University of the Free State, with our academics recognised on national and international platform.

Earning yet another accolade for the university, Dr Philemon Akach, Head of the Department of South African Sign Language, has been awarded a National Excellence in Teaching and Learning Award. The award by the Higher Education Learning and Teaching Association of Southern Africa (HELTASA) and Council on Higher Education (CHE), recognised Dr Akach as a “leader in the field of teaching and learning – with impact beyond the classroom and the institution.” Recognising his pioneering work within deaf education, HELTASA and CHE commend Dr Akach as an “inspirational practitioner who recognises the inclusion of the marginalised in education.”

Dr Akach is one of five recipients, selected out of a total of 22 candidates from across South Africa that will receive the award. The other winners are from the University of Cape Town, Stellenbosch University, University of KwaZulu-Natal and the University of Pretoria. The five winners will receive the awards at a gala dinner at the annual HELTASA conference, which takes place from 26 to 29 November 2013.

Dr Akach, who will retire at the end of 2014, says the national recognition is the cherry on top as he prepares to return to his home country. Kenya. “How good can it be?” “This is my life calling,” he said about the 37 years he worked within deaf education.

The academic also received an Alumni Award for Outstanding Service at the recent Kovsie Alumni Awards.

Pioneering work by Dr Akach:

With Dr Akach steering the process, the UFS became the first university on the continent to offer Sign Language as an academic course in 1999.
Dr Akach was part of a nine-member task team that handed over the South African Sign Language (SASL) curriculum to the Minister of Basic Education, Angie Motshekga. A member of the ministerial task team since 2009, he helped to coordinate the development of the curriculum that will soon be offered as a school subject to Grade 0–12 learners in all 42 schools for the deaf in South Africa.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept